2025 Report: “ProZenith Reviews and Complaints” Search Surge Mirrors Interest in Clean Energy Supplements Increased search volume around clean-label metabolic supplements — including queries like “ProZenith complaints” — reflects a wider shift in how consumers are navigating stimulant-free wellness solutions in North America. GlobeNewswire August 05, 2025 Los Angeles, Aug. 04, 2025 (GLOBE NEWSWIRE) — […]

(NASDAQ:PRAX), BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst

Praxis Precision Medicines to Participate in Upcoming Fireside Chat GlobeNewswire August 05, 2025 BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza

Salt Lake City, Aug. 04, 2025 (GLOBE NEWSWIRE) — A growing number of Americans are questioning the same outdated joint pain “remedies” they've relied on for years in 2025. From glucosamine pills to endless collagen powders, solutions once trusted by doctors and influencers alike are now being blamed for worsening pain — not solving it.

Why XentaFlex Is Emerging as 2025's Most Affordable, Simplest, and Most Effective Joint Pain Solution More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First Joint Hydration Formulas Like Simple Promises' XentaFlex GlobeNewswire August 05, 2025 Salt Lake City, Aug. 04, 2025 (GLOBE NEWSWIRE) — A growing number of

NEW YORK, NY / ACCESS Newswire / August 4, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159723&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 4, 2025 / If you suffered a loss on your Lockheed Martin Corporation (NYSE:LMT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=159721&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 4, 2025 / If you suffered a loss on your iRobot Corporation (NASDAQ:IRBT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/irobot-corporation-lawsuit-submission-form?prid=159722&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 4, 2025 / If you suffered a loss on your Neogen Corporation (NASDAQ:NEOG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neogen-corporation-lawsuit-submission-form?prid=159720&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB 400 million Series D financing round. The announcement was made at the Zhongguancun (Daxing) Cell and Gene Therapy Industrial Park, a key hub for Beijing's life sciences sector. Financing Co-led by Beijing Medical and Health Industry Investment Fund